---
document_datetime: 2023-09-21 17:47:27
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/nexavar-epar-procedural-steps-taken-authorisation_en.pdf
document_name: nexavar-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3838761
conversion_datetime: 2025-12-15 02:31:24.371216
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## 1 BACKGROUND INFORMATION ON THE PROCEDURE

## 1.1 Submission of the dossier

The applicant  Bayer  HealthCare  AG  submitted  on  7  September  2005  an  application  for  Marketing Authorisation  to  the  European  Medicines  Agency  (EMEA)  through  the  centralised  procedure  for Nexavar which was designated as an orphan medicinal product EU/3/04/207 on 29 July 2004. Nexavar was  designated  as  an  orphan  medicinal  product  in  the  following  indication:  treatment  of  renal  cell carcinoma.  The  calculated  prevalence  of  this  condition  was  approximately  3  per  10,000 EU population.

The applicant applied for the following indication: Nexavar is indicated for the treatment of patients with  advanced  renal  cell  carcinoma.  The  legal  basis  for  this  application  refers  to  Article  8.3  of Directive 2001/83/EC, as amended - complete and independent application, (i.e. complete dossier with administrative, quality, non-clinical and clinical data).

## Scientific Advice

The  applicant  received  Scientific  Advice  from  the  CHMP  on  15  May  2003.  The  Scientific  Advice pertained to clinical aspects of the dossier.

## Licensing status:

A new application was filed in the following countries: USA

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Tomas Salmonson

Co-Rapporteur: Beatriz Silva Lima

CHMP Peer reviewers: Jens Ersb√∏ll and Romaldas Maciulaitis

## 1.2 Steps taken for the assessment of the product

- The application was received by the EMEA on 7 September 2005.
- The Rapporteur's first Assessment Report was circulated to all CHMP members on 8 December 2005. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 12  December  2005.  During  the  meeting  on  23-26  January  2006,  the  CHMP  agreed  on  the consolidated  List  of  Questions  to  be  sent  to  the  applicant.  The  final  consolidated  List  of Questions was sent to the applicant on 26 January 2006.
- The procedure started on 28 September 2005.
- The applicant submitted preliminary responses to the CHMP List of Questions in preparation of the SAG for Oncology on 13 February 2006.
- The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on 20 February 2006.
- During  a  meeting  of  SAG  Oncology  on  9  March  2006  experts  were  convened  to  address questions raised by the CHMP. Answers and comments were given by the group on 22 March 2006.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on  24 March 2006.
- The Rapporteurs circulated an updated Joint Assessment Report to all the CHMP members on 21 April 2006.
- During the meeting on  24-27 April 2006, the CHMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing  Authorisation  to  Nexavar  on  27  April  2006.  The  applicant  provided  the  letter  of undertaking on the follow-up measures to be fulfilled post-authorisation on 25 April 2006.
- The CHMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 19 July 2006.